Acrivon Therapeutics (ACRV) Balance Sheet: Assets & Liabilities

Acrivon Therapeutics (ACRV) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Acrivon Therapeutics reported total assets of $129.72M and total liabilities of $17.20M. Shareholders' equity was $112.52M, down 36.4% from $176.79M a year earlier. Total debt stood at $2.71M against $118.58M in cash and short-term investments, a net cash position of $115.87M. That puts debt-to-equity at 0.02, compared with 0.02 a year earlier.

Acrivon Therapeutics Balance Sheet Analysis

Values in millions USD

Income Statement Balance Sheet Cash Flow Ratios

Scale:

Scroll to see more

Balance sheet showing assets, liabilities, and shareholders' equity for Acrivon Therapeutics, Inc. (ACRV) - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period ending	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Current Assets
Cash and Cash Equivalents	41.50	39.82	36.02	29.52	99.60	1.58
Short-Term Investments	77.08	139.66	91.44	98.23	0.00	0.00
Cash & Short-Term Investments	118.58	179.48	127.46	127.75	99.60	1.58
Accounts Receivable	0.00	0.00	0.00	0.00	0.00	0.00
Inventory	0.00	0.00	0.00	0.00	0.00	0.00
Other Current Assets	1.86	2.15	2.23	4.34	0.81	0.14
Total Current Assets	120.45	181.63	129.69	132.10	100.41	1.72
Non-Current Assets
Property, Plant & Equipment (Net)	7.42	8.03	7.91	6.86	5.79	0.06
Long-Term Investments	0.00	5.09	0.00	41.88	0.00	0.00
Other Non-Current Assets	0.20	0.20	0.67	0.39	0.39	0.41
Total Non-Current Assets	9.27	14.96	8.57	49.13	6.18	0.47
Total Assets	129.72	196.59	138.27	181.23	106.59	2.19
Current Liabilities
Accounts Payable	2.28	0.76	5.05	0.90	0.96	0.14
Short-Term Debt	1.17	1.06	0.88	0.73	0.66	0.06
Accrued Liabilities	6.66	9.94	7.38	2.16	0.55	0.42
Deferred Revenue	0.00	0.00	0.00	0.07	0.07	0.00
Other Current Liabilities	12.22	15.40	7.38	4.82	1.22	0.42
Total Current Liabilities	15.66	17.21	13.30	6.52	2.91	0.61
Non-Current Liabilities
Long-Term Debt	1.54	2.59	3.77	4.24	4.96	0.00
Other Non-Current Liabilities	0.00	0.00	0.00	0.00	122.52	9.99
Total Non-Current Liabilities	1.54	2.59	3.77	4.24	127.48	9.99
Total Liabilities	17.20	19.80	17.07	10.75	130.40	0.61
Stockholders' Equity
Common Stock	0.03	0.03	0.02	0.02	0.00	0.00
Retained Earnings	-274.88	-196.98	-116.42	-56.03	-24.87	-8.62
Accumulated Other Comprehensive Income	0.11	0.45	-0.08	-0.10	0.00	0.00
Additional Paid-in Capital	387.26	373.28	237.68	226.58	1.05	0.21
Shares Outstanding	31.65	31.23	22.52	21.92	18.81	-
Total Stockholders' Equity	112.52	176.79	121.20	170.48	-23.81	1.57
Total Liabilities & Equity	129.72	196.59	138.27	181.23	106.59	2.19

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Acrivon Therapeutics Balance Sheet

How much debt does Acrivon Therapeutics have?

Acrivon Therapeutics had total debt of $2.71M as of Dec 31, 2025, against $118.58M in cash and short-term investments. Its debt-to-equity ratio was 0.02. Total debt was $3.65M a year earlier.

What are Acrivon Therapeutics's total assets?

Acrivon Therapeutics reported total assets of $129.72M as of Dec 31, 2025, down 34.0% from $196.59M a year earlier. Total liabilities were $17.20M.

What is Acrivon Therapeutics's shareholders' equity?

Acrivon Therapeutics's shareholders' equity was $112.52M as of Dec 31, 2025, or about $3.56 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition